Sanofi “on track” with switch studies for Cialis and Tamiflu

10 February 2021 - Deborah Wilkes

Premium

Sanofi Consumer Healthcare is “on track” with the key studies needed to switch Cialis (tadalafil) and Tamiflu (oseltamivir) from prescription-to-OTC status in the US, according to chief science officer Josephine Fubara.

Click tags below for more information on topics:

Sanofi Consumer Healthcare

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: